Hurler's Syndrome: Clinical Trials

5 trials for Hurler's Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 3 Phase 4, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 43Completed 2, Terminated 1
Phase 21Terminated 1
Phase 31Completed 1

Follow Hurler's Syndrome: new trials by email Literature Review of Hurler's Syndrome trials Research Report on Hurler's Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
Laronidase - Mucopolysaccharidosis I, Hurler's Syndrome
Phase 4TerminatedGenzyme, a Sanofi Company22010-10-222024-02-20
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome
Phase 2TerminatedMasonic Cancer Center, University of Minnesota182008-03-012017-12-28
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) - Mucopolysaccharidosis I, Hurler's Syndrome
Phase 4CompletedGenzyme, a Sanofi Company342004-12-012015-04-03
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients
laronidase - Mucopolysaccharidosis I, Hurler's Syndrome
Phase 4CompletedGenzyme, a Sanofi Company252004-07-012014-05-05
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
Aldurazyme, placebo - Mucopolysaccharidosis I, Hurler's Syndrome
Phase 3CompletedGenzyme, a Sanofi Company452001-05-012015-04-03

Narrower conditions

Mucopolysaccharidosis I (5)  ·  Aspartylglucosaminuria (1)  ·  Fucosidosis (1)  ·  Leukodystrophy, Globoid Cell (1)  ·  Leukodystrophy, Metachromatic (1)  ·  Metabolism, Inborn Errors (1)  ·  Mucopolysaccharidosis VI (1)  ·  Mucopolysaccharidosis VII (1)  ·  Niemann-Pick Disease, Type B (1)  ·  Niemann-Pick Disease, Type C (1)  ·  Peroxisomal Disorders (1)  ·  Sphingolipidoses (1)  ·  Wolman Disease (1)  ·  alpha-Mannosidosis (1)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Connective Tissue Diseases (5)  ·  Genetic Diseases, Inborn (5)  ·  Lysosomal Storage Diseases (5)  ·  Metabolic Diseases (5)  ·  Mucinoses (5)  ·  Mucopolysaccharidoses (5)  ·  Nutritional and Metabolic Diseases (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Metabolism, Inborn Errors (4)  ·  Brain Diseases (1)  ·  Brain Diseases, Metabolic (1)  ·  Brain Diseases, Metabolic, Inborn (1)  ·  Central Nervous System Diseases (1)

Interventions

Iduronidase (4)  ·  Alemtuzumab (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Cyclophosphamide (1)  ·  Stem Cell Transplantation (1)

Sponsors

Genzyme, a Sanofi Company (4)  ·  Masonic Cancer Center, University of Minnesota (1)

Countries

United States (3)  ·  Brazil (2)  ·  Canada (2)  ·  Italy (2)  ·  Germany (1)  ·  Netherlands (1)  ·  United Kingdom (1)

Top investigators

Paul Orchard, MD (1)

Results publications

PMID 19117887, PMID 21586746, PMID 25864295, PMID 33874971